Management of cancers of the digestive system has progressed rapidly into the molecular era. Despite the significant recent achievements in the diagnosis and treatment of these patients, the number of deaths for these tumors has currently plateaued. Many investigations have assessed the role of HER2 in tumors of the digestive system in both prognostic and therapeutic settings, with heterogeneous results. Novel testing and treatment guidelines are emerging, in particular in gastric and colorectal cancers. However, further advances are needed. In this review we provide a comprehensive overview of the current state-of-knowledge of HER2 alterations in the most common tumors of the digestive system and discuss the operational implications of HER2 testing.
Keywords: Biliary tract cancer; Colon cancer; Digestive system; Esophageal cancer; Gallbladder cancer; Gastric cancer; Gastroesophageal junction cancer; Gastrointestinal tract; HER2; Liver cancer; Pancreas cancer.